CSE($CDN) XRX (Delayed) OTC($USD) XRTXF

Board of Directors


Dr. Allen Davidoff, PhD
Dr. Allen W. Davidoff, Ph.D. (15 years drug development ), Formerly, Chief Scientific officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. (seven years) ( Trillium TRIL:NASDAQ). Prior to Stem Cell Therapeutics Corp., Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp. Allen has a broad range of clinical and regulatory experience. Senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies (four multi-country), seven phase II studies, and one NDA. 12 years C- level leadership as Co-founder of Stem Cell Therapeutics Corp (Trillium Therapeutics) – A NASDAQ listed Company and XORTX Therapeutics Inc. ( XRX-CSE)

Bruce Rowlands, Chairman
Mr. Rowlands is a director of Eurocontrol Technics Group, a TSXV listed company that is focused on the acquisition and development of certification and authentication technologies.  Prior to forming Eurocontrol, Mr. Rowlands worked in the biotechnology and investment banking industries as Senior Vice President with Lorus Therapeutics, a leading Canadian biotechnology company and Vice President and Director of Dominick and Dominick Securities Canada, a Canadian investment banking firm.

Bruce Cousins, B Comm. CA
Mr. Cousins is an accomplished biopharma industry senior finance and operations executive with experience spanning small, early stage growth to large, international companies.  His prior positions in the biopharma industry include former Executive Vice President and Chief Financial Officer for both Arbutus Biopharma Corporation, a Nasdaq listed biotech company and Aspreva Pharmaceutical Inc. and Worldwide Finance Director and Worldwide Operations Controller, Johnson & Johnson. Bruce Cousins has significant public company experience, both TSX and Nasdaq as well as extensive financing and M&A experience.  He holds a Honours, Bachelor of Commerce from McMaster University and he is a Chartered Accountant with the Institute of Chartered Accountants of Ontario.

Paul Van Damme, B Comm. CPA. MBA
Paul Van Damme has held senior positions with a number of Canadian and US public companies. His experience focused on the biotech industry in Toronto when he joined GlycoDesign, a private biotech company. While at Allelix Pharmaceuticals Inc., he participated in the sale of that company to NPS Pharmaceuticals, Inc. Paul is Managing Director, WCM Capital, a Director of OncoQuest Inc. and Chief Financial Officer for Structural Genomics Consortium, a UK-based charity. He holds a B.Comm. from the University of Toronto and a MBA from the Rotman School of Management. A Chartered Professional Accountant who worked for PricewaterhouseCoopers in its Toronto and London, UK offices, he has also been appointed Chair of the XORTX Audit Committee.

Allan Williams
Allan Williams, an independent businessman, brings over 30 years capital market and public company experience to the XORTX board. During his extensive career in the mining industry and more recently the entertainment community, Allan has been instrumental in raising over $250 million in project capital. He also has extensive mergers and acquisitions experience, most recently relating to the acquisition of Calico Resources Corp., a TSX Venture listed company by Paramount Gold Nevada Corp., a New York Stock Exchange listed company. Alan is a current director of Greatbanks Resources Inc., Maritime Resources Corp., both TSX Venture listed companies and True Grit Resources Inc., a NEX listed company.